难治性甲状腺癌的靶向治疗
《难治性甲状腺癌的靶向治疗》由会员分享,可在线阅读,更多相关《难治性甲状腺癌的靶向治疗(44页珍藏版)》请在装配图网上搜索。
1、 n Thyroid cancer is the most common malignancy of the endocrine systemn 5-year disease-specific survival of patients with DTC with distant metastases is 50% (Shaha et al. 1997, Hundahl et al. 1998).n Like DTC, patients with metastatic disease do poorly, with a 5 year survival of 50% (Hundahl et al.
2、 1998).n median survival of this group of patients is 6 months duration. median PFS was 12 months Objective responsen 14% PRs, 67% SD and a 35% SD 6n months durationn median PFS was 10 monthsn 81% had decreased serum Tgn concentrations during treatment as compared with baseline Sunitinib (SU 011248)
3、 Sunitinib is approved through the FDA for patients with metastatic renal cell carcinoma or imitanib refractory gastrointestinal stromal tumors. Cohen et al. 2008an phase II study of sunitinib 37 patients with iodine-refractory progressive DTCn PR in 13%, SD in 68%, progressive disease in 10% n Goul
4、art et al. 2008,Ravaud et al. 2008 Results are awaited for other ongoing phase II trials of sunitinib in patients with iodine-refractory DTC and metastatic MTC Gefitinib n Another phase II clinical trial evaluated efficacy of vandetanib in patients with hereditary MTC(Haddad et al.2008) n 19 patient
5、s, 2 (10%) PRs and 6 (42%) SD 6 monthsn international phase III trial of vandetanib in sporadic and hereditary MTC was recently completed and the results are eagerly awaited. XL-184n XL-184 is an oral multi-kinase inhibitor targeting RET,MET and VEGFR2. In a phase I clinical trial of XL-184, 14 pati
6、ents with MTC were enrolled (Salgia et al. 2008).n Three PRs were noted among tenn evaluable MTC patients, 5696% reductions in n serum calcitonin and 580% reductions in serum CEA were noted in all ten evaluable MTC patients n a phase II trial was conducted in 18 patients with metastatic ATC, good pe
7、rformance status, and no prior therapy for disseminated disease (Cooney et al. 2006). Six patients had SDs while rest of the patients progressed. Median PFS was 1.8 months 28% of patients progression free 3 months. Median survival was 5 months. phase III study of paclitaxel and carboplatin with or w
8、ithout combretastatin is ongoing. 17-AAGn 17-AAG is a heat shock protein (Hsp) 90 inhibitor thathas been identified as a potential therapeutic agent in thyroid cancer. Hsp 90 specifically has been found to be important to the signaling kinases Akt and RAF as well as formation of the PTC1 protein, which is the most common RET/PTC chimeric oncoprotein seen in PTC (Smida et al. 1999). In preclinical studies,17-AAG was found to reduce RET/PTC1 proteinlevels, induce cell death and increase the uptake of radioactive iodine into thyroid cancer cells Motesanib
- 温馨提示:
1: 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
2: 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
3.本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
5. 装配图网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。